Cullinan Associates Inc. Buys 705 Shares of Oracle Co. (NYSE:ORCL)

Share on StockTwits

Cullinan Associates Inc. increased its stake in shares of Oracle Co. (NYSE:ORCL) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,835 shares of the enterprise software provider’s stock after acquiring an additional 705 shares during the quarter. Cullinan Associates Inc.’s holdings in Oracle were worth $1,157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of ORCL. Nuveen Asset Management LLC grew its position in Oracle by 6,437.0% during the 2nd quarter. Nuveen Asset Management LLC now owns 10,144,910 shares of the enterprise software provider’s stock worth $577,955,000 after acquiring an additional 9,989,718 shares during the last quarter. Beutel Goodman & Co Ltd. grew its position in Oracle by 62.5% during the 2nd quarter. Beutel Goodman & Co Ltd. now owns 5,578,093 shares of the enterprise software provider’s stock worth $231,296,000 after acquiring an additional 2,146,084 shares during the last quarter. DNB Asset Management AS grew its position in Oracle by 45.1% during the 4th quarter. DNB Asset Management AS now owns 5,823,307 shares of the enterprise software provider’s stock worth $308,519,000 after acquiring an additional 1,811,137 shares during the last quarter. Smith Asset Management Group LP bought a new position in Oracle during the 2nd quarter worth approximately $56,546,000. Finally, California Public Employees Retirement System grew its position in Oracle by 13.7% during the 3rd quarter. California Public Employees Retirement System now owns 8,151,315 shares of the enterprise software provider’s stock worth $448,567,000 after acquiring an additional 984,173 shares during the last quarter. Institutional investors and hedge funds own 52.24% of the company’s stock.

ORCL opened at $54.76 on Thursday. The stock has a market cap of $176.04 billion, a PE ratio of 17.33, a PEG ratio of 1.62 and a beta of 1.13. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 3.13. The business has a 50 day moving average of $54.39 and a 200-day moving average of $55.10. Oracle Co. has a 52 week low of $47.81 and a 52 week high of $60.50.

Oracle (NYSE:ORCL) last released its earnings results on Thursday, December 12th. The enterprise software provider reported $0.90 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.02. The company had revenue of $9.62 billion during the quarter, compared to analysts’ expectations of $9.65 billion. Oracle had a return on equity of 56.86% and a net margin of 27.62%. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the business posted $0.80 EPS. Equities analysts anticipate that Oracle Co. will post 3.47 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 23rd. Stockholders of record on Thursday, January 9th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.75%. The ex-dividend date of this dividend is Wednesday, January 8th. Oracle’s payout ratio is presently 30.38%.

In other news, EVP Dorian Daley sold 50,000 shares of the business’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $55.01, for a total value of $2,750,500.00. Following the completion of the transaction, the executive vice president now owns 50,000 shares in the company, valued at $2,750,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Berg sold 9,550 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $56.59, for a total value of $540,434.50. In the last 90 days, insiders sold 289,193 shares of company stock valued at $15,846,893. 36.60% of the stock is currently owned by company insiders.

A number of brokerages have recently weighed in on ORCL. Raymond James reiterated an “outperform” rating and issued a $57.00 price objective (down from $61.00) on shares of Oracle in a research report on Friday, December 13th. Needham & Company LLC reiterated a “hold” rating on shares of Oracle in a research report on Wednesday, October 30th. Credit Suisse Group set a $62.00 price objective on Oracle and gave the stock a “buy” rating in a research report on Tuesday, December 17th. Royal Bank of Canada reiterated a “neutral” rating and issued a $57.00 price objective on shares of Oracle in a research report on Thursday, December 12th. Finally, Zacks Investment Research lowered Oracle from a “hold” rating to a “sell” rating in a research report on Tuesday, November 26th. Three research analysts have rated the stock with a sell rating, nineteen have issued a hold rating and eight have issued a buy rating to the company. Oracle currently has a consensus rating of “Hold” and an average price target of $57.67.

Oracle Profile

Oracle Corporation develops, manufactures, markets, sells, hosts, and supports application, platform, and infrastructure solutions for information technology (IT) environments worldwide. The company provides services in three primary layers of the cloud: Software as a Service, Platform as a Service, and Infrastructure as a Service.

Featured Article: Using other technical indicators with support levels

Want to see what other hedge funds are holding ORCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oracle Co. (NYSE:ORCL).

Institutional Ownership by Quarter for Oracle (NYSE:ORCL)

Receive News & Ratings for Oracle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oracle and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.